$GGB

Johannpeter Andre Bier Gerdau sold $490K of GGB

Johannpeter Andre Bier Gerdau sold 99,200 shares of GERDAU S.A. (GGB) at $4.94 ($0.49M total) on 2026-08-10.

Original reporting
SEC EDGAR · Johannpeter Andre Bier Gerdau
Published Aug 12, 2026, 8:46 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 12, 2026, 9:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$GGB
Neutral
medium confidence
Mentioned
$GGB
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GGBNeutralLow
01

Why it matters

Traders may monitor insider activity for sentiment, but this filing alone does not indicate a change in company fundamentals.

02

Market read

A disclosed insider open-market sale at $4.94 is likely to have limited trading impact absent other catalysts.

03

What to watch

The text does not confirm whether the insider’s broader selling program exists, nor does it provide context on total holdings changes over time; absence of a stated 10b5-1 plan could be misread without additional filings.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-12 after-hours; sale dated 2026-08-10

Background

The article is a SEC Form 4 insider transaction disclosure for Gerdau S.A. (GGB).

Company-level read

Ticker impact

$GGBNeutralMedium confidence
Context

Gerdau insider Johannpeter Andre Bier Gerdau filed a Form 4 showing an open-market sale of 99,200 shares at $4.94 on 2026-08-10.

Expected impact

Low likelihood of a sustained price move; any reaction is likely limited to short-term sentiment around insider selling.

Evidence & confidence

This is a Form 4 insider transaction with no 10b5-1 plan stated and no accompanying fundamental catalyst in the text. Insider sales are often non-informational, so impact is likely modest unless traders treat the lack of 10b5-1 as a signal.

Market effects

Minimal. One insider sale does not provide new information about steel/industrial demand or pricing.

Minimal. The disclosure is company-specific and not tied to a regional macro event.

Minimal. No deal, guidance, or regulatory action is described.

Counterpoint

The sale may be routine diversification or liquidity management, especially since the filing is an open-market transaction without any stated performance or corporate event linkage.

Key entities

  • Gerdau S.A.

    Subject of the Form 4 insider transaction disclosure.

  • Johannpeter Andre Bier Gerdau

    Insider who sold 99,200 shares in an open-market sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$GGBMed

Gerdau (GGB) Q3 2026 Earnings Call Transcript

Gerdau S.A. reported Q3 2026 earnings, highlighting BRL 1.7B free cash flow, BRL 0.34/share dividends, and a solid balance sheet. The company expects to return over BRL 1.85B to shareholders in 2026. North American operations showed strong demand, while Brazil faced seasonal slowdowns and import challenges. The company plans adjustments to improve Brazilian profitability and is awaiting government support on trade and energy policies.

$GGBMed

What Gerdau (GGB) Said on Its Q3 Earnings Call

Gerdau (GGB) is expanding capacity at its Texas facility, with full production expected by 2027. The company focuses on organic investments, not spin-offs or major acquisitions. Management discussed potential trade impacts on regional margins. In Brazil, Gerdau faces import pressure but plans productivity improvements. The company announced dividends and reduced capital expenditure plans to BRL 4 billion. Net debt to EBITDA is 0.58 times, with a positive outlook from S&P.

$GGBMedAI 8/10

Gerdau ADR earnings missed, revenue topped estimates

Gerdau ADR (GGB) reported Q3 EPS of $0.159, missing estimates of $0.165, while revenue of $3.75B exceeded expectations. The stock is down 4.23% over 3 months but up 37.28% year-over-year. Analysts revised EPS positively twice in the last 90 days. InvestingPro rates its financial health as good.